Long-Term Outcomes of Chemoradiation for Anal Cancer Patients.
10.3349/ymj.2013.54.1.108
- Author:
Hun Jin KIM
1
;
Jung Wook HUH
;
Chang Hyun KIM
;
Sang Woo LIM
;
Taek Keun NAM
;
Hyeong Rok KIM
;
Young Jin KIM
Author Information
1. Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Jeollanam-do, Korea. jwhuh@hotmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Anal cancer;
concurrent chemoradiation;
prognosis
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Anus Neoplasms/*drug therapy/*radiotherapy;
Chemoradiotherapy/*methods;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Lymphatic Metastasis;
Male;
Middle Aged;
Prognosis;
Proportional Hazards Models;
Recurrence;
Time Factors;
Treatment Outcome
- From:Yonsei Medical Journal
2013;54(1):108-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to evaluate long-term oncologic outcomes after concurrent chemoradiation treatment for anal cancer. MATERIALS AND METHODS: Between January 1979 and December 2008, the records of 50 consecutive patients with anal cancer and who were treated by chemoradiation or radiation only with a curative intent were retrospectively reviewed. The oncologic outcomes and the risk factors for recurrence were analyzed. RESULTS: Of the 50 patients, 49 underwent concurrent chemoradiation and one underwent radiation only. After these definitive treatments, 43 (86.0%) achieved a clinical complete response. During the median follow-up of 60 months (range: 2-202 months), the 5-year overall survival, disease-free survival, and locoregional recurrence-free survival were 84.2%, 72.7%, and 69.9%, respectively. Multivariate analysis revealed that the performance status (p=0.031) and a clinical complete response (p=0.039) were the independent predictors for overall survival; lymph node involvement (p=0.031) was the only independent predictor for disease-free survival. CONCLUSION: The performance status and a clinical complete response may be reliable predictors of survival after chemoradiation for anal cancer. The addition of irradiation to the inguinal area may not be significantly associated with the outcomes.
